Oral peptideOral tablet · Study regimen
Phase 2Registered; not yet recruiting; estimated start November 2026
← Therapy pipeline
Investigational · Obesity development
LY4086940
Oral GGG peptide · oral triple agonist · Eli Lilly
Investigational oral GLP-1/GIP/glucagon triple agonist peptide with a newly registered Phase 2 obesity study.
GLP-1GIPglucagon
Obesity stagePhase 2
Phase 1Phase 2Phase 3Regulatory review
Updated as of November 2026SponsorEli Lilly
TargetsGLP-1 + GIP + glucagon
RouteOral tablet
DevelopmentObesity-specific
Results availability
No numerical results shown
Phase 1 is completed with no registry results posted. Phase 2 is registered and not yet recruiting; no Phase 2 efficacy or safety results are available.
Mechanism at a glance
GLP-1GLP-1Targeted
GIPGIPTargeted
GCGglucagonTargeted
AMYamylin—
OTHOther targets—
Obesity stage by formulation
Milestone → next
Latest: Phase 2 W8M-MC-OG01 (NCT07890376) first posted October 22, 2026. Not yet recruiting as reviewed October 26; estimated start November 2026. Phase 1 completed August 5, 2026.
Next: Phase 2 initiation and dose-ranging results. Primary weight endpoint at week 32; secondary weight endpoint at week 48. Estimated primary completion January 2028 and study completion June 2028; dates may change.
Clinical study records
Obesity and weight-management studies appear first. Related-condition trials follow by phase, with focus labels to show what each study evaluates. Study stage and results reporting are listed separately. Results summarized above are identified as peer-reviewed or sponsor reported. Otherwise, the label states whether results were posted to a registry or reported in the linked source.
Obesity and weight-management studies
Phase 2 studies1 record
W8M-MC-OG01 · Phase 2 obesity dose-ranging
Weight managementStudy: Planned / not yet recruitingResults: No registry results posted yetStatus reviewed November 2026
Planned randomized, double-blind, parallel-group, placebo-controlled study under master protocol CWMM (NCT06143956). Approximately 460 adults aged 18–75 with obesity or overweight plus a weight-related health condition, without type 2 diabetes. Nine oral active-treatment groups test six dose levels and different titration schedules, plus oral placebo; dose strengths and dosing frequency are not specified in the public record. Primary endpoint: percent change in body weight at week 32; secondary endpoints include weight change at week 48, weight-related quality of life and pharmacokinetics. Participation lasts about 58 weeks. Estimated start November 2026; primary completion January 2028; overall completion June 2028.
Related conditions and outcomes
Phase 1 studies1 record
J5U-MC-YGAA · first-in-human safety and pharmacokinetics
Safety and pharmacokinetics; mixed populationStudy: CompletedResults: No registry results posted yetStatus reviewed November 2026
Completed randomized, double-blind study; 219 participants enrolled. Included healthy participants and participants with overweight or obesity, with or without type 2 diabetes. Evaluated safety, tolerability and pharmacokinetics. Primary safety endpoint assessed study-drug-related serious adverse events through week 9; secondary endpoints included maximum concentration and exposure. Started April 23, 2025; completed August 5, 2026. No results posted to the registry.